{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-022354","form_type":"8-K","ticker":"RVPH","cik":"0001742927","company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","filed_at":"2024-07-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.382280+00:00","generated_at":"2026-05-31T22:37:59.800288+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"European patent granted covering brilaroxazine for pulmonary hypertension; adds to US, China, Japan patents","bullets":["European Patent EP3244896 granted covering brilaroxazine for treating PH, PAH, including PH in COPD or SCD patients.","Similar patents already granted in United States, China, and Japan for brilaroxazine in PH/PAH.","Brilaroxazine has Orphan Drug Designation from FDA for treatment of pulmonary arterial hypertension.","CEO cites anti-inflammatory/antifibrotic activity in animal models; plans to evaluate PH/PAH expansion."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-022354","json":"https://secwatch.observer/filing/0001437749-24-022354.json","markdown":"https://secwatch.observer/filing/0001437749-24-022354.md","text":"https://secwatch.observer/filing/0001437749-24-022354.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1742927/000143774924022354/0001437749-24-022354-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1742927/000143774924022354/rvph20240709_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T22:37:59.800288+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}